ask our doctors

Thrombocytosis Essential

Get the facts on Thrombocytosis Essential treatment, diagnosis, staging, causes, types, symptoms. Information and current news about clinical trials and trial-related data, Thrombocytosis Essential prevention, screening, research, statistics and other Thrombocytosis Essential related topics. We answer all your qestions about Thrombocytosis Essential.

Question: Can you give blood with essential thrombocytosis? I might have essential thrombocytosis and I would really like to give blood, but I don't know if I can if I really do end up having it.

Answer: why risk it


Thrombocytosis Essential News

CHMP recommends EU approval for Novartis' Jakavi to treat patient with ...

pharmabiz.com
As part of the Novartis clinical development programme, Jakavi is being investigated in primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. Jakavi is also being investigated in clinical trials ...
 

Highlights of presentations planned for ASCO meeting

The Pharma Letter
The company will feature progress of Jevtana in mCRC, Zaltrap + prednisone in metastatic hormone-refractory prostate cancer; SAR302503 in primary myelofibrosis, postpolycythemia vera MF, or post-essential thrombocythemia MF with splenomegaly; ...
 

Incyte's Potential Blockbuster Pipeline Asset Makes It An Attractive Takeover ...

Seeking Alpha
In addition, INCY has seen a strong launch of Jakafi -- an indicated for treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia ...
 

Analyst says Incyte's pipeline makes it attractive takeover candidate

Proactive Investors USA & Canada
In addition, INCY has seen a strong launch of Jakafi-- an indicated for treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post?polycythemia vera myelofibrosis and post?essential thrombocythemia ...
 

Incyte achieves regulatory milestone under ruxolitinib license agreement with ...

Pharmaceutical Business Review
The recommendation by the CHMP of the EMA for approval of ruxolitinib to treat of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia ...
 

Geron Corporation Reports 2012 First Quarter Financial Results and Highlights

Reuters
Imetelstat is a telomerase inhibitor that is being evaluated in four Phase 2 clinical trials: metastatic breast cancer, advanced non-small cell lung cancer, essential thrombocythemia and multiple myeloma. GRN1005 is a peptide-drug conjugate that is ...
 

Geron Completes Enrollment in Phase 2 Clinical Trial of Imetelstat in Non ...

Reuters
Imetelstat is a telomerase inhibitor that is being evaluated in four Phase 2 clinical trials: metastatic breast cancer, advanced non-small cell lung cancer, essential thrombocythemia and multiple myeloma. GRN1005 is a peptide-drug conjugate that is ...
 

Novartis drug Jakavi(TM) recommended by CHMP for EU approval to treat patients ...

PipelineReview.com (press release)
... for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.
 

Geron Announces Conference Call to Discuss First Quarter 2012 Financial Results

MarketWatch (press release)
Imetelstat is a telomerase inhibitor that is being evaluated in four Phase 2 clinical trials: metastatic breast cancer, advanced non-small cell lung cancer, essential thrombocythemia and multiple myeloma. GRN1005 is a peptide-drug conjugate that is ...
 

Novartis receives CHMP backing for myelofibrosis drug

Zenopa
Jakavi is specified for adult patients with primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis and would become the first EU-approved JAK inhibitor for this deadly disease.